Cargando…
Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance
Chemotherapy resistance and relapses are common in high-risk neuroblastoma (NB). Here, we developed a clinically relevant in vivo treatment protocol mimicking the first-line five-chemotherapy treatment regimen of high-risk NB and applied this protocol to mice with MYCN-amplified NB patient-derived x...
Autores principales: | Mañas, Adriana, Aaltonen, Kristina, Andersson, Natalie, Hansson, Karin, Adamska, Aleksandra, Seger, Alexandra, Yasui, Hiroaki, van den Bos, Hilda, Radke, Katarzyna, Esfandyari, Javanshir, Bhave, Madhura Satish, Karlsson, Jenny, Spierings, Diana, Foijer, Floris, Gisselsson, David, Bexell, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616506/ https://www.ncbi.nlm.nih.gov/pubmed/36306349 http://dx.doi.org/10.1126/sciadv.abq4617 |
Ejemplares similares
-
Anti-tumor effects of rigosertib in high-risk neuroblastoma
por: Radke, Katarzyna, et al.
Publicado: (2021) -
Patient-derived models: Advanced tools for precision medicine in neuroblastoma
por: Aaltonen, Kristina, et al.
Publicado: (2023) -
The Iroquois homeobox proteins IRX3 and IRX5 have distinct roles in Wilms tumour development and human nephrogenesis
por: Holmquist Mengelbier, Linda, et al.
Publicado: (2018) -
Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma
por: Mohlin, Sofie, et al.
Publicado: (2019) -
Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma
por: Mohlin, Sofie, et al.
Publicado: (2020)